ArrowMark Colorado Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-19,055	Closed	-$2.98M	–	331
2014 Q2	$2.98M	Hold	19,055	–	–	0.08%	173
2014 Q1	$2.9M	Sell	19,055 -175	-0.9%	-$27.8K	0.09%	167
2013 Q4	$2.56M	Buy	19,230 +730	+4%	+$87.6K	0.08%	167
2013 Q3	$2.15M	Hold	18,500	–	–	0.07%	180
2013 Q2	$1.71M	Buy	+18,500	New	+$1.78M	0.46%	54

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

ArrowMark Colorado Holdings's ALXN Position: Q3 2014 in Review

ArrowMark Colorado Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q3 2014, closing a stake of 19,055 shares — an estimated $2.98M sold.

ArrowMark Colorado Holdings first reported a position in ALXN in Q2 2013 and held it in 5 quarters. The position peaked at $2.98M in Q2 2014. 522 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

ArrowMark Colorado Holdings reported no remaining Alexion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
ArrowMark Colorado Holdings sold 19,055 Alexion Pharmaceuticals shares in Q3 2014, an estimated $2.98M.
ArrowMark Colorado Holdings first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 5 quarters.
ArrowMark Colorado Holdings's Alexion Pharmaceuticals position peaked at $2.98M in Q2 2014.
522 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2014, filed 14 Nov 2014.